17-07-2008Latest Results - Q2 2008

Novartis gains momentum with strong performance in first half of 2008 from portfolio focused on growth areas of healthcare

13-05-2008International presentation of clinical safety and efficacy data for Binocrit®, the world’s first complex biosimilar

• - First international presentation of clinical evidence supporting a biopharmaceutical approved by the biosimilar regulatory process
• - Data demonstrate safety and efficacy of Binocrit® in anemia treatment
• - Sandoz further confirms pioneering position in biosimilars, enhancing patient access to high-quality, affordable biopharmaceuticals

30-04-2008Sandoz Receives Regulatory Guidance on Enoxaparin ANDA

Expects to Submit Amendment to ANDA in Third Quarter, 2008

21-04-2008Latest Results - Q1 2008

Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle

12-03-2008Sandoz enhances patient access with launch of Omnitrope™ Pen 5

- New delivery system enables patient convenience
- Priced 35% below the originator product, furthering patient access to Omnitrope, first follow-on version of a recombinant biotechnology drug

17-01-2008Novartis results 2007

Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio

16-01-2008Sandoz fully cooperating with European Commission investigation of the pharmaceuticals industry

08-01-2008Sandoz and Gambro form strategic alliance

- Cooperation in the launch of biosimilar Binocrit® into selected European markets
- Joining forces in the area of hemodialysis to increase opportunities for treatment of chronic kidney disease

18-10-2007Latest Results - Q3 2007

Novartis delivers record earnings in first nine months of 2007 thanks to strong operational performance and divestment gains

31-08-2007European Commission Approval for biosimilar epoetin alfa

The European Commission's decision to grant this approval followed a positive opinion in June from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP), which reviews medicines scientifically for the Commission.